Knowthestock.com
AKTX - Akari Therapeutics Plc
We couldn't determine Recommendation based on the data we have.




Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Akari Therapeutics Plc (AKTX) - http://akaritx.com
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
Exchange - NASDAQ
Industry - Pharmaceuticals: Major
Sector - Health Technology
CEO - Clive Stuart Richardson
Employees - 10
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.